These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7273791)

  • 1. Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" result.
    Chlebowski RT; Weiner JM; Ryden VM; Bateman JR
    Control Clin Trials; 1981 Jun; 2(2):123-32. PubMed ID: 7273791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
    Conlin AK; Seidman AD
    J Natl Compr Canc Netw; 2007 Sep; 5(8):668-72. PubMed ID: 17927924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.
    Chlebowski RT; Irwin LE; Pugh RP; Sadoff L; Hestorff R; Wiener JM; Bateman JR
    Cancer Res; 1979 Nov; 39(11):4503-6. PubMed ID: 387216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-dose chemotherapy in breast cancer].
    Schmid P; Possinger K
    Med Klin (Munich); 2002 Nov; 97(11):677-86. PubMed ID: 12434276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination versus sequential single-agent therapy in metastatic breast cancer.
    Miles D; von Minckwitz G; Seidman AD
    Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of breast cancer: current views and results.
    Bonadonna G; Valagussa P
    Int J Radiat Oncol Biol Phys; 1983 Mar; 9(3):279-97. PubMed ID: 6341335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer.
    Carter SK
    Breast Cancer Res Treat; 1981; 1(1):43-51. PubMed ID: 6184098
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer.
    Powles TJ; Coombes RC; Smith IE; Jones JM; Ford HT; Gazet JC
    Lancet; 1980 Mar; 1(8168 Pt 1):580-2. PubMed ID: 6102295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer.
    Edelstyn GA; Bates TD; Brinkley D; MacRae KD; Spittle MF; Wheeler T
    Lancet; 1975 Aug; 2(7927):209-11. PubMed ID: 51964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chemotherapy on survival in metastatic breast cancer.
    Paterson AH; Szafran O; Cornish F; Lees AW; Hanson J
    Breast Cancer Res Treat; 1981; 1(4):357-63. PubMed ID: 7348580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of results of chemotherapy trials in metastatic breast cancer.
    J Clin Oncol; 1986 Feb; 4(2):258-61. PubMed ID: 3511185
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of chemotherapy of survival in metastatic breast cancer.
    Paterson AH; Lees AW; Hanson J; Szafran O; Cornish F
    Lancet; 1980 Aug; 2(8189):312. PubMed ID: 6105455
    [No Abstract]   [Full Text] [Related]  

  • 17. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
    Ahmann DL; Green SJ; Bisel HF; Ingle JN; Hahn RG; Lee RA; Edmonson JH
    Am J Clin Oncol; 1982 Aug; 5(4):355-8. PubMed ID: 7051804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.